Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Familial Amyloid Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.02.54

    Familial Amyloid Polyneuropathy

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.54 alerts

    Get alerted when Policy 05.02.54 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Onpattro and Wainua in adults with polyneuropathy due to hereditary transthyretin-mediated amyloidosis, including preferred products, exception criteria, documentation, dosing limits, and continuation requirements.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyFamilial Amyloid Polyneuropathy
    Policy CodePolicy 05.02.54
    Change TypeNo material change
    Effective DateSep 27, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit testing or analysis confirming a mutation of the TTR gene.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Therapies with detailed approval criteria
    18+Minimum age for initial approval
    9 moInitial approval duration
    12 moContinuation approval duration
    3 vials/21 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Onpattro quantity limit
    1/monthWainua quantity limit

    Coverage Criteria

    Onpattro Initial Therapy

    Onpattro (patisiran) may be considered medically necessary when ALL of the following criteria are met:

    ALL of the following

    • Member is 18 years of age or older
    • Member has a diagnosis of hereditary ATTR amyloidosis with polyneuropathy confirmed by the presence of a TTR gene mutation (e.g., V30M)
    • Member has a polyneuropathy disability (PND) score ≤ IIIb (see Appendix A) or a familial amyloid polyneuropathy (FAP) disease stage ≤ 2 (see Appendix C)
    • Member has clinical signs and symptoms of polyneuropathy (i.e., weakness, sensory loss, decreased motor strength, decreased gait speed)
    • Other causes of peripheral neuropathy have been assessed and ruled out (see Appendix B)
    • Member is receiving Vitamin A supplementation at the recommended daily allowance prior to initiating therapy with the requested drug and will continue to receive it for the duration of treatment
    • Member will not be receiving the requested medication in combination with tafamidis (Vyndaqel, Vyndamax), acoramidis (Attruby), eplontersen (Wainua), or vutrisiran (Amvuttra)

    Wainua Initial Therapy

    Wainua (eplontersen) may be considered medically necessary when BOTH the Preferred Drug Plan Design and ALL of the following initial approval criteria are met:

    ALL of the following

    • ONE of the following Preferred Drug Plan Design criteria

      • Member has had an inadequate response to treatment, an intolerable adverse event, or a contraindication to therapy with the preferred products, Onpattro (patisiran) and Amvuttra (vutrisiran)
      • Member is currently receiving therapy with Wainua, excluding when Wainua is obtained as samples or through a manufacturer's patient assistance program, and is experiencing a positive therapeutic outcome
    • ALL of the following initial approval criteria

      • Member is 18 years of age or older

    Continuation Therapy

    Continuation of therapy may be granted when ALL of the following criteria are met:

    ALL of the following

    • Member continues to meet all applicable initial approval criteria
    • Member has achieved a therapeutic response, as evidenced by stabilization or improvement from baseline in polyneuropathy disability (PND), familial amyloid polyneuropathy (FAP) disease stage, or another assessment of disease progression and neuropathy severity (i.e., modified Neuropathy Impairment Scale+7 [mNIS+7] composite score, Norfolk Quality of Life-Diabetic Neuropathy [QoL-DN] total score, or neuropathy impairment score [NIS])

      Documentation from the medical record must be provided.

    Non-Formulary Exception

    A non-formulary medication may be covered when the applicable Criteria for Approval AND ALL of the following criteria are met:

    ALL of the following

    • The requested drug is used for an FDA-approved indication or an indication supported in the compendia of current literature (e.g., AHFS, Micromedex, or current accepted guidelines). Diagnostic testing or laboratory results are required when applicable.
    • The prescribed dose and quantity fall within FDA-approved labeling or dosing guidelines found in the compendia of current literature.
    • All covered formulary alternative drugs on any tier will be ineffective, have been ineffective, would not be as effective as the non-formulary drug, or would have adverse effects.

      Documentation is required and must include chart notes or other documentation indicating prior treatment failure, severity of the adverse event (if any), dosage and duration of prior treatment, or contraindication to formulary alternatives.

    The requested medication must not be used in combination with tafamidis (Vyndaqel or Vyndamax), acoramidis (Attruby), patisiran (Onpattro), eplontersen (Wainua), or vutrisiran (Amvuttra), as applicable to the requested product. Coverage for a non-preferred product is provided based on clinical circumstances that exclude use of the preferred product and may be based on previous use of a product; the coverage review process will determine whether a clinical exception can be made.

    Amvuttra (vutrisiran) criteria for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults are addressed in a separate Amvuttra drug policy.

    Coding and Clinical Thresholds

    Provider service billing codesHCPCS
    J0222Injection, Patisiran (Onpattro), 0.1 mg
    C9311Injection, Eplontersen,(Wainua) 1 mg (10/1/2026)
    Minimum age
    Minimum age18 years or older
    Applies toInitial approval for Onpattro and Wainua
    Member requirementThe member must be an adult
    Polyneuropathy Disability Score
    Permitted PND scoreIIIb or lower
    PND IIIbWalking with the help of two sticks or crutches
    AssessmentPolyneuropathy Disability Score (PND)

    Authorization and Provider Requirements

    Prior Authorization

    Prior Authorization and Preferred Products

    Prior authorization is required for products covered under this policy. Coverage applies only when the requested drug is used for an FDA-approved indication or supported compendial use and all applicable approval criteria are met. Nonpreferred products may be approved when clinical circumstances exclude use of the preferred product.

    • Preferred products: Onpattro (patisiran) and Amvuttra (vutrisiran).
    • Targeted/nonpreferred product: Wainua (eplontersen).
    • Amvuttra requests for cardiomyopathy or other drug-specific indications should be reviewed under the applicable Amvuttra policy.
    Prior Authorization

    Initial Authorization

    For initial authorization, submit documentation showing that the member meets all applicable clinical criteria for the requested product. Initial approval is available for 9 months.

    • Member must be at least 18 years old.
    • Diagnosis must be hereditary ATTR amyloidosis with polyneuropathy confirmed by a TTR gene mutation, such as V30M.

    Disease Background

    Hereditary transthyretin amyloidosis is an autosomal dominant disorder caused by mutations in transthyretin-encoding genes. Misfolded transthyretin proteins can deposit in organs and tissues, causing progressive and potentially fatal neuropathy and cardiomyopathy. Onpattro and Wainua target hepatic transthyretin production for treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis.

    Clinical Definitions

    Polyneuropathy Disability Score (PND)
    Stage 0No impairment
    Stage ISensory disturbances but preserved walking capability
    Stage IIImpaired walking capability but able to walk without a stick or crutches
    Stage IIIaWalking only with the help of one stick or crutch
    Stage IIIbWalking with the help of two sticks or crutches
    Stage IVConfined to a wheelchair or bedridden
    Familial Amyloid Polyneuropathy (FAP) stages

    Initial Therapy

    Onpattro Initial Approval

    Onpattro may be considered medically necessary when ALL of the following criteria are met.

    ALL required criteria

    • Member is 18 years of age or older.
    • Member has hereditary ATTR amyloidosis with polyneuropathy confirmed by the presence of a TTR gene mutation, such as V30M.
    • ONE of

      • Polyneuropathy Disability (PND) score is ≤ IIIb.
      • Familial Amyloid Polyneuropathy (FAP) disease stage is ≤ 2.

    Continuation Therapy

    Continuation Therapy

    Continuation may be granted when ALL initial criteria remain satisfied and a therapeutic response is documented.

    ALL continuation requirements

    • Member continues to meet all initial approval criteria.
    • Member has achieved a therapeutic response demonstrated by stabilization or improvement from baseline in PND, FAP disease stage, or another assessment of disease progression and neuropathy severity, such as the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score, Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score, or Neuropathy Impairment Score (NIS).Stabilization or improvement from baseline

      Documentation from the medical record must be provided.

    Preferred Product Step

    StepRequirement for Wainua initial approval
    1The member has had an inadequate response to treatment, an intolerable adverse event, or a contraindication to therapy with the preferred products Onpattro (patisiran) and Amvuttra (vutrisiran), unless the member is currently receiving Wainua with a positive therapeutic outcome.

    Quantity Limits

    Onpattro (patisiran)
    ProductOnpattro (patisiran)
    Quantity limit3 vials
    Frequency limitPer 21 days
    Wainua (eplontersen)
    ProductWainua (eplontersen)
    Quantity limit1 autoinjector or syringe
    Dosing scheduleOnce monthly

    Administration Setting

    Billing Rule

    Use the appropriate site of care

    Onpattro and Amvuttra require administration by a healthcare provider, while Wainua can be self-administered. Arrange the administration setting accordingly.

    Billing Rule

    Confirm administration requirements

    Amvuttra and Onpattro require administration by a healthcare provider; Wainua can be self-administered. Confirm the planned administration method before treatment.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyFamilial Amyloid Polyneuropathy
    Policy CodePolicy 05.02.54
    Change TypeNo material change
    Effective DateSep 27, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit testing or analysis confirming a mutation of the TTR gene.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Provider RequirementsDisease BackgroundClinical DefinitionsInitial TherapyContinuation TherapyPreferred Product StepQuantity LimitsAdministration Setting
    Member has a diagnosis of hereditary ATTR amyloidosis with polyneuropathy confirmed by the presence of a TTR gene mutation (e.g., V30M)
  1. Member has a polyneuropathy disability (PND) score ≤ IIIb (see Appendix A) or a familial amyloid polyneuropathy (FAP) disease stage ≤ 2 (see Appendix C)
  2. Member has clinical signs and symptoms of polyneuropathy (i.e., weakness, sensory loss, decreased motor strength, decreased gait speed)
  3. Other causes of peripheral neuropathy have been assessed and ruled out (see Appendix B)
  4. Member is receiving Vitamin A supplementation at the recommended daily allowance prior to initiating therapy with the requested drug and will continue to receive it for the duration of treatment
  5. Member will not be receiving the requested medication in combination with tafamidis (Vyndaqel, Vyndamax), acoramidis (Attruby), patisiran (Onpattro), or vutrisiran (Amvuttra)
  6. Familial Amyloid Polyneuropathy disease stage
    Permitted FAP stageStage 2 or lower
    FAP stage 2Requires assistance for walking
    AssessmentFamilial Amyloid Polyneuropathy (FAP) disease stage
    Onpattro standard quantity limit
    MedicationOnpattro (patisiran)
    Standard quantity limit3 vials per 21 days
    Limit typeStandard quantity/dosing limit
    Onpattro dosing under 100 kg
    MedicationOnpattro (patisiran)
    Patient weightLess than 100 kg
    FDA-recommended dose0.3 mg/kg every 3 weeks
    Onpattro dosing at or above 100 kg
    MedicationOnpattro (patisiran)
    Patient weight100 kg or more
    FDA-recommended dose30 mg every 3 weeks
    Wainua dosing
    MedicationWainua (eplontersen)
    Dose45 mg
    Administration scheduleSubcutaneous injection once monthly
  7. Baseline disease severity must be PND score ≤ IIIb or FAP disease stage ≤ 2.
  8. Clinical signs and symptoms of polyneuropathy must be present, and other causes of peripheral neuropathy must have been assessed and ruled out.
  9. The member must receive vitamin A supplementation at the recommended daily allowance before treatment and throughout therapy.
  10. The requested drug must not be used with the prohibited transthyretin therapies or stabilizers listed in the product-specific criteria.
  11. Prior Authorization

    Continuation Authorization

    For continuation authorization, document that the member continues to meet the initial approval criteria and has achieved a therapeutic response. Approval for continuation is for 12 months when the required response documentation is submitted.

    • Document stabilization or improvement from baseline in PND score, FAP disease stage, or another assessment of disease progression and neuropathy severity.
    • Relevant assessments may include mNIS+7, Norfolk QoL-DN total score, or NIS.
    • Medical-record documentation is required.
    Step Therapy

    Wainua Preferred-Product Step

    Wainua is subject to the preferred-product requirement. Initial authorization for Wainua may be granted when the member has an inadequate response, intolerable adverse event, or contraindication to preferred therapy, or when the member is already receiving Wainua and experiencing a positive therapeutic outcome.

    • Preferred products include Onpattro (patisiran) and Amvuttra (vutrisiran).
    • Current Wainua therapy does not qualify if Wainua was obtained as samples or through a manufacturer patient-assistance program.

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Failure to Meet Clinical Criteria

    Initial authorization may be denied when the member does not meet the required clinical criteria for the requested product.

    • Member is younger than 18 years of age.
    • Hereditary ATTR amyloidosis with polyneuropathy or a confirming TTR mutation is not documented.
    • PND score exceeds IIIb and FAP disease stage exceeds 2, or baseline severity is not documented.
    • Clinical signs and symptoms of polyneuropathy are absent or other causes of peripheral neuropathy have not been assessed and ruled out.
    • Required vitamin A supplementation is not documented.
    • A required product-specific or other approval criterion is not met.
    Denial Risk

    Prohibited Combination Therapy

    The requested medication must not be administered concurrently with specified transthyretin therapies or stabilizers. Requests involving prohibited combination therapy may be denied.

    • Onpattro may not be used in combination with tafamidis (Vyndaqel or Vyndamax), acoramidis (Attruby), Wainua (eplontersen), or Amvuttra (vutrisiran).
    • Wainua may not be used in combination with tafamidis (Vyndamax or Vyndaqel), acoramidis (Attruby), Onpattro (patisiran), or Amvuttra (vutrisiran).
    Denial Risk

    Preferred Product Requirement

    Wainua may be denied when the preferred-product step is not met. The request must document an inadequate response, intolerable adverse event, or contraindication to preferred Onpattro or Amvuttra, unless the member is already receiving Wainua with a positive therapeutic outcome under the policy's requirements.

    • Use of Wainua obtained through samples or a manufacturer patient-assistance program does not establish qualifying current therapy.
    • The preferred-product exception must be supported by clinical documentation.
    Denial Risk

    Nonformulary Exception Not Established

    A nonformulary exception may be denied when the requested drug does not meet the policy's indication, dosing, quantity, or alternative-therapy requirements.

    • The requested indication is not FDA-approved or supported by current compendia or guidelines.
    • The requested dose or quantity exceeds FDA labeling or accepted compendial dosing guidelines.
    • Covered formulary alternatives have not been shown to be ineffective, less effective, associated with adverse effects, or contraindicated.
    • Required diagnostic testing, laboratory results, or documentation of prior treatment failure, adverse-event severity, dosage, duration, or contraindication is missing.
    Stage 0Asymptomatic
    Stage 1Sensory neuropathy
    Stage 2Requires assistance for walking
    Stage 3Bedridden or wheelchair bound
    Other causes of peripheral neuropathy
    Metabolic and nutritional causesDiabetes, glucose intolerance, vitamin B12 deficiency, and vitamin B6 toxicity
    Inherited or treatment-related causesCharcot-Marie-Tooth disease and chemotherapeutic agents, including platins, vincristine, taxanes, lenalidomide, and thalidomide
    Inflammatory or autoimmune causesVasculitis and autoimmune diseases such as Sjögren's syndrome, lupus, and rheumatoid arthritis
    Systemic causesTrauma and chronic kidney disease
    Cancer-related causeParaneoplastic syndrome
    Infectious causesViral infections, including varicella-zoster, herpes simplex, Lyme disease, West Nile, cytomegalovirus, and HIV
    Member has clinical signs and symptoms of polyneuropathy, such as weakness, sensory loss, decreased motor strength, or decreased gait speed.
  12. Other causes of peripheral neuropathy have been assessed and ruled out.
  13. Member is receiving Vitamin A supplementation at the recommended daily allowance before initiating Onpattro and will continue supplementation for the duration of treatment.
  14. Member will not receive Onpattro in combination with tafamidis (Vyndaqel or Vyndamax), acoramidis (Attruby), Wainua (eplontersen), or Amvuttra (vutrisiran).
  15. Wainua Initial Approval

    Wainua may be considered medically necessary when the preferred drug plan design and ALL clinical criteria are met.

    ALL required criteria

    • Member is 18 years of age or older.
    • Member has hereditary ATTR amyloidosis with polyneuropathy confirmed by the presence of a TTR gene mutation, such as V30M.
    • ONE of

      • Polyneuropathy Disability (PND) score is ≤ IIIb.
      • Familial Amyloid Polyneuropathy (FAP) disease stage is ≤ 2.
    • Member has clinical signs and symptoms of polyneuropathy, such as weakness, sensory loss, decreased motor strength, or decreased gait speed.
    • Other causes of peripheral neuropathy have been assessed and ruled out.
    • Member is receiving Vitamin A supplementation at the recommended daily allowance before initiating Wainua and will continue supplementation for the duration of treatment.
    • Member will not receive Wainua in combination with tafamidis (Vyndaqel or Vyndamax), acoramidis (Attruby), Onpattro (patisiran), or Amvuttra (vutrisiran).
    • ONE preferred-product exception or continuation pathway

      • Member has had an inadequate response to, an intolerable adverse event from, or a contraindication to treatment with both preferred products, Onpattro (patisiran) and Amvuttra (vutrisiran).
      • Member is currently receiving Wainua, excluding therapy obtained as samples or through a manufacturer’s patient assistance program, and is experiencing a positive therapeutic outcome.